Kconfab: A familial breast cancer consortium facilitating research and translational oncology

Journal of the National Cancer Institute - Monographs

Volumn , Issue 43, 2011, Pages 79-81

  Thorne, Heather ^a   Mitchell, Gillian ^a   Fox, Stephen ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; B RAF KINASE INHIBITOR; BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER PREVENTION; CANCER RESEARCH; CANCER SCREENING; DNA REPAIR; FAMILIAL CANCER; GENE MUTATION; GENETIC SCREENING; GENOMIC INSTABILITY; HUMAN; PRIORITY JOURNAL; AUSTRALIA; BREAST TUMOR; CLINICAL TRIAL (TOPIC); DRUG EFFECT; FEMALE; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; METHODOLOGY; MUTATION; NEW ZEALAND; ONCOLOGY; ORGANIZATION AND MANAGEMENT; PATIENT SELECTION; TRANSLATIONAL RESEARCH; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; AUSTRALIA; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; MEDICAL ONCOLOGY; MUTATION; NEW ZEALAND; PATIENT SELECTION; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84855172217     PISSN: 10526773     EISSN: 17456614     Source Type: Book Series    
DOI: 10.1093/jncimonographs/lgr042     Document Type: Article

References (8)

1. Finkel E. Australia takes a two-step approach on genetic studies. Science. 1998, 280: 1831-1832.
2. Easton DF, Pooley KA, Dunning AM, et al. A genome-wide association study identifies multiple novel breast cancer susceptibility loci. Nature. 2007, 447(7148): 1087-1093.
3. Lim E. Vaillant F, Wu D, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nature Med. 2009, 15(8): 907-913.
4. Price MA, Butow P, Lo S, et al. Predictors of cancer worry in unaffected women from high-risk breast cancer families: risk perception is not the primary issue. J Genet Couns. 2007, 16: 635-644.
5. Framer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005, 434(7035): 917-921.
6. Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010, 376(9737): 235-244.
7. Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010, 376(9737): 245-251.
8. Flaherty KT, McArthur G. BRAF, a target in melanoma: implications for solid tumor drug development. Cancer. 2010, 116(21): 4902-4913. Review.